Treatment strategy in adrenocortical carcinomas Fase II trial with docetaxel and cisplatin in patients with locally advanced or disseminated adrenocortical carcinomas

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-001341-42-DK

Enrollment

Registered

2006-02-10

Start date

2006-03-10

Completion date

Unknown

Last updated

2021-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fase II trial of taxotere and cisplatin in patients with advanced or metastatic adrenocortical carcinoma

Interventions

Trade Name: Cisplatin Product Name: Cisplatin Pharmaceutical Form: Intravenous infusion INN or Proposed INN: Cisplatin Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Conce

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adrenocortical carcinoma no possibility for operation age > 18 years performance 0 or 1 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: performance 2 or less other cancer diseases

Design outcomes

Primary

Measure	Time frame
Main Objective: Response rate;Secondary Objective: Toxicity time to progression;Primary end point(s): Response rate	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026